{"id":62925,"date":"2026-04-13T07:03:08","date_gmt":"2026-04-13T05:03:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/"},"modified":"2026-04-13T07:03:08","modified_gmt":"2026-04-13T05:03:08","slug":"number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/","title":{"rendered":"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026"},"content":{"rendered":"
\n

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News:<\/p>\n

<\/a>
<\/a><\/p>\n

\nPursuant to the article L. 233-8 II of the French \u201cCode de Commerce\u201d and the article 223-16 of the French stock-market authorities (Autorit\u00e9 des March\u00e9s Financiers<\/i>, or \u201cAMF<\/b>\u201d) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate<\/b>\u201d or the \u201cCompany<\/b>\u201d) releases its total number of shares outstanding as well as its voting rights as of April 9, 2026:<\/p>\n\n\n\n\n
\n

\nTotal number of shares outstanding:<\/p>\n<\/td>\n

<\/td>\n\n

\n93,860,680<\/p>\n<\/td>\n

<\/td>\n\n

\nshares<\/p>\n<\/td>\n<\/tr>\n

\n

\nincluding:<\/p>\n<\/td>\n

<\/td>\n\n

\n93,847,763<\/p>\n

\n5,336<\/p>\n

\n7,581<\/p>\n<\/td>\n

<\/td>\n\n

\nordinary shares<\/p>\n

\nPreferred Shares 2016<\/p>\n

\nPreferred Shares 2017<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal number of theoretical voting rights (1):<\/p>\n

\nTotal number of exercisable voting rights (2):<\/p>\n<\/td>\n

<\/td>\n\n

\n94,484,443<\/p>\n

\n94,465,868<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(1) The total number of theoretical voting rights (or \u201cgross\u201d voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.<\/i><\/p>\n

\n(2) The total number of exercisable voting rights (or \u201cnet\u201d voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.<\/i><\/p>\n

\nAbout Innate Pharma<\/b><\/p>\n

\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n

\nInnate Pharma is advancing a portfolio of differentiated potential first and\/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.<\/p>\n

\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n

\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n

\nLearn more about Innate Pharma at www.innate-pharma.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n

\nInformation about Innate Pharma shares<\/b><\/p>\n\n\n
\n

\nISIN code<\/b>
Ticker code<\/b>
LEI<\/b><\/p>\n<\/td>\n

<\/td>\n\n

\nFR0010331421<\/p>\n

\nEuronext: IPH Nasdaq: IPHA<\/p>\n

\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nDisclaimer on forward-looking information and risk factors<\/b><\/p>\n

\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website (http:\/\/www.amf-france.org<\/a>) or on Innate Pharma\u2019s website (www.innate-pharma.com<\/a>), and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n

\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor additional information, please contact:<\/b>
Investors & Media Relations<\/span><\/b>
Innate Pharma<\/b>
St\u00e9phanie Cornen
\n
stephanie.cornen@innate-pharma.fr<\/a><\/p>\n

\nInvestor Relations<\/b>
investors@innate-pharma.fr<\/a><\/p>\n

\nMedia<\/b>
communication@innate-pharma.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Pursuant to the article L. 233-8 II of the French \u201cCode de Commerce\u201d and the article 223-16 of the French stock-market authorities (Autorit\u00e9 des March\u00e9s Financiers, or \u201cAMF\u201d) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) releases its total number of shares outstanding as well … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62925","6":"format-standard","7":"category-industry"},"yoast_head":"\nNumber of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Pursuant to the article L. 233-8 II of the French \u201cCode de Commerce\u201d and the article 223-16 of the French stock-market authorities (Autorit\u00e9 des March\u00e9s Financiers, or \u201cAMF\u201d) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) releases its total number of shares outstanding as well ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T05:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260412718494\/en\/2770759\/22\/5841494cINNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026\",\"datePublished\":\"2026-04-13T05:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/\"},\"wordCount\":638,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260412718494\\\/en\\\/2770759\\\/22\\\/5841494cINNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/\",\"name\":\"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260412718494\\\/en\\\/2770759\\\/22\\\/5841494cINNATEvertnoirDS.jpg\",\"datePublished\":\"2026-04-13T05:03:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260412718494\\\/en\\\/2770759\\\/22\\\/5841494cINNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260412718494\\\/en\\\/2770759\\\/22\\\/5841494cINNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/","og_locale":"en_US","og_type":"article","og_title":"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Pharma Trend","og_description":"MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Pursuant to the article L. 233-8 II of the French \u201cCode de Commerce\u201d and the article 223-16 of the French stock-market authorities (Autorit\u00e9 des March\u00e9s Financiers, or \u201cAMF\u201d) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) releases its total number of shares outstanding as well ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-13T05:03:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260412718494\/en\/2770759\/22\/5841494cINNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026","datePublished":"2026-04-13T05:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/"},"wordCount":638,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260412718494\/en\/2770759\/22\/5841494cINNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/","url":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/","name":"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260412718494\/en\/2770759\/22\/5841494cINNATEvertnoirDS.jpg","datePublished":"2026-04-13T05:03:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260412718494\/en\/2770759\/22\/5841494cINNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260412718494\/en\/2770759\/22\/5841494cINNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/number-of-shares-and-voting-rights-of-innate-pharma-as-of-april-9-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62925"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62925\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}